BioSpace News Archive

OSF Ventures has joined four other organizations this week in supporting Series ‘A’ funding of $7.3 million for Washington, DC-based health care technology start-up Socially Determined which offers data analytics to identify patients who face barriers to better health.

More than 1,000 members of the global ADHD community will convene in Philadelphia from November 7 through 9 for the 2019 Annual International Conference on ADHD.

Hyperfine Research Inc. is introducing the world’s first low-cost, point-of-care (POC) magnetic resonance imaging (MRI) system at the American College of Emergency Physicians (ACEP) Scientific Assembly 2019.

Public safety members and first responders are facing challenges today as never before. The toll of the job is exacting and goes far beyond the physical demands.

Inland Empire Health Plan (IEHP) continues to improve community health by collaborating with key local partners to present the Move the Needle Summit, set for Tuesday, October 29, at the Way World Outreach in San Bernardino.

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has filed a prior approval supplement (PAS) for ranitidine hydrochloride injection

PitchBook, the premier data provider for the private and public equity markets, will release nine Emerging Technology Research reports in Q4 2019 to expand coverage of new sectors, including healthtech, IoT, information security and supply chain tech.

VoxNeuro provides the only neuroimaging tool that goes beyond diagnosis to inform cognitive rehabilitation.

Two inventors, from Lancaster, Calif., wanted to create a safe and secure way to walk or rest when using a walker, so they invented the HOPE SAFETY WALKER.

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announced that data reported in two abstracts at SMSNA add to the growing body of data supporting the safety and efficacy of the Company’s MED2005 topical gel for the treatment of erectile dysfunction (ED)